Healio4d
FDA receives biologics license application for apitegromab in spinal muscular atrophy
A Boston-area biopharmaceutical firm has submitted a biologics license application to the FDA for its investigational, fully ...
Candel initiated at buy by Citi, lead immunotherapy drugs cited
BofA has initiated coverage of Candel Therapeutics (NASDAQ:CADL) with a buy rating, citing the potential of its immunotherapy drug candidates CAN-2409 and CAN-3110. "While approved therapies may have ...
Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease
Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of ...
Business Wire9d
Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA)
today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration (FDA) for apitegromab, a muscle-targeted therapy designed and developed to provide ...
Morningstar24d
FDA accepts Biologics License Application for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US
has accepted BioArctic's partner Eisai's Biologics License Application (BLA) for Leqembi subcutaneous autoinjector (SC-AI) for weekly maintenance dosingLeqembi is indicated for the treatment of ...
Pharm Exec10d
FDA Approves Supplemental Biologics License Application for Intravenous Maintenance Dosing of Leqembi in Alzheimer Disease
Approval was based on results from multiple studies, which demonstrated a slowing of cognitive decline in patients with ...
Enveric Biosciences Inks Two Licensing Agreements With Restoration Biologics To Treat Joint Disease
Enveric Biosciences’ (NASDAQ:ENVB) wholly-owned subsidiary, Akos Biosciences, Inc., entered into two licensing agreements ...